Clinical trial
Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency
NCT00261833 · CSL Behring, Industry · Completed
Key facts
| NCT number | NCT00261833 |
|---|---|
| Title | Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency |
| Official title | A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to Compare the Efficacy and Safety of 60mg/kg Body Weight of Zemaira® Weekly I.V. Administration With Placebo Weekly I.V. Administration in Chronic Augmentation and Maintenance Therapy in Subjects With Emphysema Due to… |
| Lead sponsor | CSL Behring, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Alpha1-proteinase Inhibitor Deficiency, Emphysema |
| Intervention type | Biological, Other |
| Interventions | Alpha1-proteinase inhibitor, Placebo |
| Enrollment | 180 |
| Start date | Mar 1, 2006 |
| Primary completion | Sep 1, 2012 |
| Completion | Sep 1, 2012 |
| First posted | Dec 5, 2005 |
| Last update posted | Jan 19, 2015 |
| Countries | Australia, Canada, Czechia, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Russia, Sweden and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: